The GPRC5A Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte cell line. This product provides a loss-of-function model in which the gene encoding the orphan G protein-coupled receptor GPRC5A has been disrupted via CRISPR/Cas9-mediated genome editing. The resulting polyclonal pool contains a heterogeneous mixture of edited alleles, offering a robust system to study the functional consequences of GPRC5A ablation without clonal selection bias.
Jurkat cells are an immortalized human T lymphocyte cell line originally derived from an acute lymphoblastic leukemia patient. They serve as a well-established model for T cell receptor signaling, calcium flux, and downstream transcriptional events. The cell line retains key signaling machinery, making it a cornerstone in immunological and oncological research, particularly for dissecting the molecular mechanisms underlying T cell activation and malignant transformation.
GPRC5A encodes an orphan class C G protein-coupled receptor that is implicated in modulating intracellular cAMP and calcium levels. It is thought to couple through G?? proteins such as G??s and G??q, linking to adenylyl cyclase-cAMP-PKA-CREB and calcium-dependent signaling cascades. GPRC5A has been reported to interact with ??-arrestin scaffolding proteins, and its expression is regulated by retinoic acid. Downstream of GPRC5A, key effectors include NF-??B, STAT3, and ERK1/2, suggesting its role in integrating mitogenic and stress-responsive pathways.
In the Jurkat T lymphocyte context, loss of GPRC5A disrupts potential GPCR-mediated regulation of T cell receptor-proximal events and downstream signaling. This knockout model enables researchers to dissect how GPRC5A influences calcium flux, cAMP homeostasis, and the activation of transcription factors such as NF-??B and STAT3 in a malignant T cell background. The system is particularly relevant for understanding leukemogenic signaling and evaluating the tumor-suppressive or modulatory functions attributed to GPRC5A in various cancers.
Included in a typical application are phospho-signaling analyses such as ERK1/2 phosphorylation assessment by Western blotting, cAMP quantification using bioluminescence resonance energy transfer or ELISA-based assays, and calcium flux measurements via fluorescent indicators. The GPRC5A Knockout Jurkat Polyclonal Cells are also suitable for drug screening campaigns targeting GPCR modulators, apoptosis and migration assays, and transcriptomic profiling by RNA-seq or RT-qPCR. For additional information, please contact Ascent Research.
